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Summary
Plague caused by the Gram-negative bacterium, Yersinia pestis, is still 
endemic in parts of the world today. Protection against pneumonic plague 
is essential to prevent the development and spread of epidemics. Despite 
this, there are currently no licensed plague vaccines in the western world. 
Here we describe the means of delivering biologically active plague vac-
cine antigens directly to mucosal sites of plague infection using highly 
stable microvesicles (outer membrane vesicles; OMVs) that are naturally 
produced by the abundant and harmless human commensal gut bacterium 
Bacteroides thetaiotaomicron (Bt). Bt was engineered to express major 
plague protective antigens in its OMVs, specifically Fraction 1 (F1) in the 
outer membrane and LcrV (V antigen) in the lumen, for targeted delivery 
to the gastrointestinal (GI) and respiratory tracts in a non-human primate 
(NHP) host. Our key findings were that Bt OMVs stably expresses F1 
and V plague antigens, particularly the V antigen, in the correct, immu-
nogenic form. When delivered intranasally V-OMVs elicited substantive 
and specific immune and antibody responses, both in the serum [immu-
noglobulin (Ig)G] and in the upper and lower respiratory tract (IgA); this 
included the generation of serum antibodies able to kill plague bacteria. 
Our results also showed that Bt OMV-based vaccines had many desirable 
characteristics, including: biosafety and an absence of any adverse effects, 
pathology or gross alteration of resident microbial communities (micro-
biotas); high stability and thermo-tolerance; needle-free delivery; intrinsic 
adjuvanticity; the ability to stimulate both humoral and cell-mediated im-
mune responses; and targeting of primary sites of plague infection.
Keywords: antibodies, gut bacteria, humoral immunity, mucosal vaccine, 
non-human primates, outer membrane vesicles, plague
Introduction
Plague is caused by the Gram-negative bacterium, 
Yersinia pestis. It is an ancient disease, accounting for 
many deaths over hundreds of years, and still exists 
in parts of the world today. To protect against infec-
tion vaccines must be able to elicit both humoural 
immunity with neutralizing antibodies and cell-mediated 
immunity that is effective at primary mucosal sites of 
infection [1,2].
There are currently no licensed plague vaccines in the 
western world. In the past, heat-killed whole-cell vaccines 
(listed in the US Pharmacopeia) were available and pro-
vided protection against bubonic, but not pneumonic plague. 
However, due to unacceptable reactogenicity these vaccines 
were discontinued [3]. Live-attenuated vaccines have been 
used in countries of the former Soviet Union and China 
although, due to unacceptable reactogenicity and the risk 
of reversion to full virulence, they have not been licensed 
for use elsewhere, including the United States [4].
Fraction 1 (F1) and LcrV (virulence; V antigen) Y. 
pestis proteins encoded by the Fra/pMT1 and pCD1 
plasmids, respectively [5], have been identified as the 
major protective antigens responsible for preventing 
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phagocytosis of Y. pestis (F1) and regulating type III 
secretion (V antigen) [6]. The present emphasis on 
developing F1- and V antigen-based vaccines is on 
recombinant protein-based subunit  vaccines (rF1V) that 
incorporate chemical adjuvants. If a Y. pestis variant 
occurs with a mutation in the V antigen then these 
F1-V vaccines may not provide protection via immunity 
to the V component; however, immunity to the F1 
component could still provide some limited protection 
[7,8]. In addition, the duration of protection against 
pneumonic infection provided by these as a subunit 
vaccine, in which the F1 and V antigens are presented 
as a fusion protein, is also uncertain [9]. Furthermore, 
the requirement for injection by needle to deliver these, 
and other current vaccines, is problematical. It is associ-
ated with: risks of cross-contamination; lack of patient 
compliance; the high cost of mass immunization; and 
a requirement for cold chain delivery and storage. 
Importantly, injected vaccines provide only partial or 
no protection at the primary mucosal site of plague 
infection [2,10]. Collectively, these issues constrain the 
use of existing plague vaccines, particularly in resource-
poor low-income settings, and these restrictions are 
reflected in the World Health Organization (WHO)’s 
draft therapeutic product profile [11].
The use of nanoparticle-based platforms is a new 
approach to the development of more effective mucosal 
vaccines against pathogens such as those that cause the 
plague. These include virus-like particles, immune stimu-
lating complexes, polymeric nanoparticles, inorganic nano-
particles, liposomes and emulsions  –  all of which have 
the potential to overcome the high production costs and 
safety concerns associated with live vaccines and the weak 
immunogenicity and adjuvanticity issues associated with 
subunit and recombinant protein-based vaccines [10]. 
These nanoscale carrier technologies enable conformation-
ally correct antigens to be incorporated into highly stable 
nanoparticles. This allows for control over the spatial and 
temporal presentation of antigens to the immune system, 
leading to their targeted and sustained release. An over-
looked component of platform nanoscale vaccines are 
bacterial microvesicles, and in particular, outer membrane 
vesicles (OMVs) of Gram-negative bacteria [12]. While 
many synthetic nanoparticles are capable of transferring 
heterologous antigens to antigen-presenting cells (APC), 
the ability to efficiently stimulate the immune system is 
often not inherent [13]. However, OMVs can combine 
high stability with antigen presentation and native adju-
vanticity, making them an attractive vaccine platform for 
further development [14].
OMV production by vesiculation is a fundamental char-
acteristic of Gram-negative bacteria that is unrelated to 
bacterial lysis or membrane instability that fulfils the key 
requirements of a prokaryotic secretion process [15]. 
Nanoscale OMV proteoliposomes that contain immuno-
genic components derived from the bacterial outer mem-
brane and periplasm are capable of targeting APCs 
[including dendritic cells (DC)] [16–18], leading to T and 
B cell immunity. Recent research on OMVs from patho-
genic bacteria, including Neisseria meningitidis and Vibrio 
cholerae, supports the case for their being good vaccine 
candidates [19]; OMVs derived from N. meningitidis have 
been used safely and effectively as vaccine platforms for 
the control of serogroup B meningococcal (MenB) disease 
outbreaks [20,21]. OMV-based vaccines offer significant 
advantages over conventional vaccines because they are: 
non-replicating; provide needle-free delivery; target 
mucosal sites; have an established safety record; can elicit 
innate and antigen-specific adaptive immune responses; 
and possess self-adjuvant properties [i.e. microbe associ-
ated molecular pattern molecules (MAMPs) such as 
lipopolysaccharide (LPS)]. The current limitations of 
pathogen-derived, OMV vaccines are: the potential for 
unintended toxicity due to associated toxins; low expres-
sion levels of protective antigens; variable efficacy depending 
on source and formulation; the need for exogenous adju-
vants; and only incomplete protection because of strain 
variation. In principle, these limitations could be overcome 
by using OMVs from non-pathogenic commensal bacteria, 
engineered to improve their application as vaccines. In 
support of this, it has recently been shown that OMVs 
produced by the common human commensal gut bacte-
rium, Bacteroides thetaiotaomicron (Bt), are able to access 
and influence the host’s intestinal epithelial and immune 
cells [22,23]. This identifies a means by which commensal 
gut bacteria can influence host cell physiology.
Here we describe the development of a novel vaccine 
delivery technology, based on engineering Bt, to express 
the V and F1 antigens of Y. pestis in their OMVs for 
targeted delivery to the gastrointestinal (GI) and respira-
tory tracts in a non-human primate (NHP) host. Our 
findings demonstrate that OMV-based plague vaccines are 
an effective means of eliciting both mucosal and systemic 
antibody responses and systemic cell-mediated responses. 
Delivery of OMV vaccines via the respiratory route was 
particularly effective at eliciting production of antigen-
specific IgG antibodies that were protective in two inde-
pendent surrogate assays.
Materials and methods
Bacteria, media, growth conditions and 
transformations
Strains of Escherichia coli were grown in Luria–Bertani 
medium at 37°C. Bt strain VPI-5482 and derivative strains 
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were grown under anaerobic conditions at 37°C in brain 
heart infusion (BHI) medium (Oxoid, Basingstoke, UK) 
supplemented with 0·001% haemin (BHIH) or with 
0·00005% haemin for OMV preparations. Antibiotics were 
added as selective agents when appropriate: ampicillin 
200  μg/ml and erythromycin 5  μg/ml. The E. coli strain 
J53/R751 was supplemented with trimethoprim 200  μg/
ml when grown for 18  h. E. coli GC10 was transformed 
by electroporation using a Gene Pulser II (Bio-Rad, Watford, 
UK). Plasmids were mobilized from E. coli into Bt fol-
lowing a triparental filter mating protocol [24] using the 
helper strain J53/R751. The Y. pestis strain CO92 (biovar 
Orientalis, NR641; BEI Repositories) was supplied by the 
Biodefence and Emerging Infections (BEI) Research 
Repository (Bethesda, MD, USA) in accordance with 
International Export and Import Regulatory Requirements 
and used with kind permission from National Institute 
of Allergy and Infectious Diseases (NIAID). The organism 
was stored and handled in accordance with US Biological 
Select Agent or Toxin requirements and was grown using 
the conditions and methods described previously [25].
Construction of Y. pestis F1- and V1-antigen expression 
vectors
A synthetic gene construct of 1043 base pairs (bp) encod-
ing the V antigen and a synthetic operon construct of 
3826 bp encoding caf1M, caf1A and caf1 genes of the 
caf1 operon that generates the F1 protein were N-terminally 
fused to the OmpA signal peptide of Bt. This created 
in-silico constructs with codon usages optimized for expres-
sion in the same species. Signal peptide prediction was 
obtained by SignalP at http://www.cbs.dtu.dk/services/
SignalP/. During the design of the synthetic constructs 
the unique Bacteroides ribosomal binding site [26] required 
for efficient expression in Bacteroides was accounted for. 
The resulting gene cassettes for V and F1 were obtained 
through gene synthesis and subsequently cloned into the 
E. coli plasmids pEX-A2 and pEX-K4 (Eurofins, Hamburg, 
Germany), respectively. The cassettes contained BspHI and 
EcoRI restriction sites at their 5′ and 3′ ends, respectively, 
allowing for the translational fusion of the encoded gene 
to the start codon in the Bacteroides expression vector 
pGH090 [26]. The genes encoding V1 or F1 were excised 
from the pEX derivatives using BspHI and EcoRI and 
ligated into the NcoI/EcoRI-restricted pGH090 expression 
vector, resulting in pGH179 and pGH180, respectively. 
Finally, the sequence integrity of the cloned fragments 
was verified through sequencing.
OMV isolation and characterization
OMVs were isolated following a method adapted from 
Stentz et al. [27]. Briefly, cultures of Bt (500  ml) were 
centrifuged at 5500  g for 45  min at 4°C and the 
supernatants filtered through polyethersulphone (PES) 
membranes (0·22  μm pore-size) (Sartorius, Göttingen, 
Germany) to remove debris and cells. Supernatants were 
concentrated by ultrafiltration (100  kDa molecular weight 
cut-off, Vivaspin 50R; Sartorius), the retentate was rinsed 
once with 500  ml of phosphate-buffered saline (PBS) (pH 
7.4) and concentrated to 1  ml (approx. 700  µg/ml total 
protein). The final OMV suspensions were filter-sterilized 
(0·22  µm pore size). The protein content of the final 
OMV suspensions was determined using the Bio-Rad 
Protein Assay.
The distribution of heterologous proteins within Bt OMVs 
was established in a proteinase K accessibility/protection 
assay [27]. Briefly, a suspension of 250  μg of OMVs in 
0·1  M phosphate/1  mM ethylenediamine tetraacetic acid 
(EDTA) buffer (pH 7.0) was incubated for 1  h at 37°C 
in the presence of 100  mg/l proteinase K (Sigma-Aldrich, 
Poole, UK). Proteinase K activity was stopped by addition 
of 1  mM phenylmethanesulphonyl fluoride (PMSF) and 
samples analysed by immunoblotting.
Nanoparticle analysis
Videos were generated using a Nanosight nanoparticle 
instrument (NanoSight Ltd, Malvern, PA, USA) to count 
OMV numbers in each OMV sample. The mean squared 
displacement (X) was measured simultaneously for each 
OMV tracked. The particle diffusion coefficient (Dt), and 
hence sphere equivalent hydrodynamic radius (rh) were 
determined using the Stokes–Einstein equation,
Dt=
kBT
6휋휂rh
 ,
where kB is Boltzmann’s constant, T is temperature and 
η is solvent viscosity.
Immunoblotting
OMV-V extracts were added to sodium dodecyl sulphate–
polyacrylamide gel electrophoresis (SDS-PAGE) loading 
buffer (NuPage; Invitrogen, Carlsbad, CA, USA) containing 
dithiothreitol (Invitrogen). Approximately 7 μg of OMV-V 
was loaded onto 12% precast Tris–glycine gels (Novex/
ThermoFisher Scientific, Fremont, CA, USA) and separated 
by electrophoresis at 180  volts for 40  min. Gels were 
transferred onto a polyvinylidene difluoride membrane at 
25  volts over 2  h in a solution containing Tris–glycine 
transfer buffer (Novex). The membrane was blocked with 
10% bovine serum albumin (BSA) in Tris-buffered saline 
(TBS) (50  mM Tris-HCl, 150  mM NaCl, pH 7.5)-Tween 
(0·05%) for 30  min at 20°C. Blocking solution was then 
discarded and the membrane incubated for 16  h at 4°C 
in a 1  : 1000 dilution of a primary mouse anti-V antibody 
(Defence Science and Technology Laboratory, Porton 
Down, UK) in TBS-Tween with 5% BSA. After washing 
with TBS-Tween three times, membranes were incubated 
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for 1  h at 20°C in 5% BSA in TBS-Tween with a 1  :  1000 
dilution of horseradish peroxidase (HRP)-conjugated goat 
anti-rabbit IgG (ThermoFisher). After three washes in 
TBS-Tween, SuperSignal West Pico chemiluminescent 
Substrate (ThermoFisher) was used to detect bound 
antibody.
The F1 content of F1-OMV formulations was determined 
using a dot-blot assay in which serial twofold dilutions 
of extracts of F1-OMVs (10  μl) were spotted onto nitro-
cellulose membranes and air-dried. Serial dilutions of 
recombinant F1 protein (rF1) and extracts of native OMVs 
were also applied to the membranes. The membranes were 
then processed as described for immunoblotting as above, 
using a rabbit anti-F1 anti-sera (Defence Science and 
Technology Laboratory) and a secondary HRP-conjugated 
goat anti-rabbit IgG (ThermoFisher). Localization of F1 
in Bt OMV preparations was determined by liquid chro-
matography and mass spectrometry (LC-MS)-based pro-
teomics (Proteomics Facility, University of Bristol, Bristol, 
UK).
Cytokine analysis
Frozen PBMCs obtained from whole blood by density 
gradient centrifugation over Ficoll-Paque Plus (Amersham 
Biosciences, Chalfont St Giles, UK) were thawed, washed 
twice with RPMI media containing 10% FBS, 2  mM glu-
tamine and 100 U/ml penicillin/streptomycin and adjusted 
to a concentration of 5  ×  105 cells/ml. Aliquots of 106 
cells were plated into individual U wells of 96-well plates 
and incubated in triplicate with media alone or media 
containing 15  μg/ml rV protein for 72  h at 37°C in an 
incubator with 5% CO2. Control cultures contained media 
only. Conditioned media was then harvested, and cytokine 
content determined using a bead-based multiplex assay 
and BD LSRFortessa flow cytometer (BD Biosciences, San 
Jose, CA, USA), according to the manufacturer’s instruc-
tions (BioLegend, San Diego, CA, USA).
Antibody enzyme-linked immunosorbent assay 
(ELISA)
Nunc-Immuno Microwell 96-well plates (ThermoScientific) 
were coated with 15 μg/ml of Y. pestis V (BG032/VDJPE1) 
or F (BG032/FD5Pst2) recombinant proteins (Defence 
Science and Technology Laboratory) in ELISA coating 
buffer (0·1  M NaHCO3) and incubated for 16  h at 4°C. 
After washing three times with ELISA wash buffer (PBS 
with 1  : 2000 Tween-20), plates were blocked for 3  h 
with blocking buffer (PBS with 2% BSA) at 20°C with 
gentle agitation. Serum, saliva, salivary gland and bron-
choalveolar lavage (BAL) samples were added in dilutions 
ranging from 1 to 163  840 and the plates were incubated 
for 16 h at 4°C. After six washes with ELISA wash buffer, 
50  μl of 1  :  10  000 goat anti-monkey immunoglobulin 
(Ig)G peroxidase conjugated (Sigma; A2054-1ml) or 
1  :  10  000 goat anti-monkey IgA–HRP antibody (Sigma; 
SAB3700759) were added and plates were incubated for 
1 h at 20°C with gentle agitation. Plates were then washed 
six times with ELISA wash buffer and incubated with 
100  μl of TMB high sensitivity substrate solution 
(BioLegend, San Diego, CA, USA) for 20  min at 20°C 
in darkness. The reaction was stopped by adding 50  μl 
of 2  N H2SO4. The plates were analysed in a microplate 
reader at Abs450 nm. Absolute amounts of IgG and IgA 
antibodies in serum and mucosal samples, respectively, 
were determined using a modified ELISA incorporating 
a range of concentrations of purified monkey IgG (Bio 
Rad) and IgA (Life Diagnostics, Inc., West Chester, PA, 
USA) and the protocol and reagents described above to 
generate standard curves from which IgG and IgA con-
centrations of individual animals were determined.
Bactericidal assay
This prototype bactericidal assay (BCA) was developed 
in a series of experiments which optimized incubation 
times, using a standard anti-rF + rV anti-serum generated 
in cynomolgus macaques. All activities associated with 
the BCA assay were performed at ACDP3 level contain-
ment within a BSL3 safety cabinet.  Y. pestis  CO92, origi-
nally sourced by Public Health England (PHE) from the 
BEI research repository (catalogue number: NR-641) was 
used to make a working stock. Working stock was propa-
gated on Columbia blood (COH) agar for 2  days at 26°C. 
A bacterial suspension was then created by harvesting 
the bacteria from the surface of the agar and subsequent 
resuspension in TSB. Sterile TSB broth was then inocu-
lated with sufficient bacterial suspension to result in an 
OD600nm of 0·1. After 3 h incubation at 26°C, the mid-log 
culture was diluted to an expected Y. pestis concentration 
of 3·3  ×  103 colony-forming units (CFU)/ml ready for 
use as the inoculum for the bactericidal assay. This process 
was used in all protocols.
Heat-treated (to deplete individual sample complement) 
primate sera were incubated with live Y. pestis bacteria 
in the presence of 25% v/v rabbit complement (Pellfreeze 
Biologicals, Roger, AR, USA) for 1  h with orbital agita-
tion on a 96-well plate shaker. After this incubation, the 
mixture was plated onto COH agar and permitted to be 
absorbed into the agar at 37°C. In preliminary experi-
ments, human volunteer and baby rabbit complement 
(Pellfreeze Biologicals) were found to be similar in sen-
sitivity to antibody-directed bactericidal activity against 
Y. pestis CO92. After this incubation, the mixture was 
plated onto COH agar and permitted to be absorbed 
into the agar. The COH plates were then incubated at 
37°C for 2 days before manual enumeration to determine 
relative viability. Incubation at 37°C only began once the 
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antibody, complement and bacterial mixture was created 
in the assay plate. This protocol simulated the natural 
infection process that would take place once a flea has 
bitten a mammalian host. No-antibody, complement-only 
controls were included in all assays.
The number of bacteria counted for each test serum 
anti-serum was used to calculate the degree of reduction 
in counts compared with the plate spread with the no-
antibody complement control. The dose of test serum 
[expressed as percentage (v/v) of serum] required to kill 
50% of live Y. pestis CO92 was calculated by interpolation 
of the dose response curve for each sample. Each assess-
ment was conducted in duplicate. Bactericidal antibody 
assessment assays were conducted at PHE on samples 
taken on each of the 4 sample days with serum pools 
from each of the 12 vaccine groups. In all studies, the 
reference standard anti-rV plus anti-rF1 primate serum 
was also assessed as a means of comparison and measure 
of reproducibility. In all studies, this standard anti-serum 
killed Y. pestis in a reproducible manner. All controls 
(including the no-antibody, complement-only no antibody 
control) were assessed and performed as expected.
Competitive ELISA
A competitive ELISA (CE-ELISA) assay was used (as 
previously described [1]) to detect antibodies in immune 
sera from V-OMV immunized animals that were able to 
compete with a monoclonal antibody (mAb 7·3) for bind-
ing to recombinant V protein. Briefly, rV antigen was 
coated onto 96-well microtitre plates (Dynex, Lincoln, UK) 
at 5  μg/m1 in 0·05  ml PBS (16–18  h, 4°C). After washing 
in PBS with 0·02% Tween 20, plates were blocked with 
0·2  ml 5% w/v skimmed milk powder in PBS (37°C, 1  h). 
After further washing, 0·05  ml mAb 7·3 (1  :  32000 in 
1% w/v skimmed milk powder in PBS) was added to 
each well (equivalent to 80 ng/well) and plates were incu-
bated at 4°C for 16  h. Normal, non-immune NHP serum, 
also diluted to 1  :  32 000, was added to negative control 
wells (0·05 ml per well). Plates were then washed prior 
to adding the test serum at a dilution of 1  :  10 in 1% 
w/v skimmed milk powder in PBS. A positive control 
was included comprising a reference serum created by 
pooling equal aliquots of sera from four macaques previ-
ously parenterally immunized with rF1 + rV antigens and 
prior to surviving challenge with Y. pestis. Test and control 
serum samples were assayed in duplicate. Plates were 
incubated (1  h, 37°C) prior to washing and addition of 
HRP-goat anti-mouse IgG (Serotec, Kidlington, UK; 
1  :  2000 in PBS) followed by incubation (37°C, 1  h). 
Plates were washed prior to addition of ABTS substrate 
(Sigma) with subsequent reading of absorbance at 414 nm. 
The optical diameter (OD)414nm determined for each test 
and the reference serum was adjusted by subtraction of 
the OD414nm determined for the appropriate control serum. 
The data were calculated from a titration curve for loss 
of binding of the mouse antibody, with increased con-
centration of human serum.
Ethics statement
All animals used in these studies were cynomolgus 
macaques (Macaca fasciculuaris) obtained from the char-
acterized breeding colonies managed by PHE that have 
been established and maintained as closed colonies for 
more than 20  years. Animals were housed in compatible 
social groups, in accordance with the Home Office (UK) 
Code of Practice for the Housing and Care of Animals 
Bred, Supplied or Used for Scientific Purposes, December 
2014, and the National Committee for Refinement, 
Reduction and Replacement (NC3Rs), Guidelines on 
Primate Accommodation, Care and Use, August 2006. 
All animals were aged between 3 and 5 years and none 
of the animals had been used previously for experimental 
procedures, were free of herpes B-virus, tuberculosis (TB), 
simian immunodeficiency virus (SIV) and simian T-cell 
leukemia virus (STLV) and were inspected by the named 
veterinary surgeon prior to entry into the study. All animal 
procedures and study design were approved by the Public 
Health England, Porton Down Animal Welfare and Ethical 
Review Committee, and authorized under an appropriate 
UK Home Office project licence (30/2993 and P76404B45).
Generation of standard NHP reference anti-sera
In order to enable development of a functional biological 
assay of relevance to these studies, anti-sera to F1 and 
V were generated by immunizing two cynomolgus 
macaques with either recombinant F1 (batch BG032\
FD5Pst2; Defence Science and Technology Laboratory) or 
recombinant V (batch BG032\VDJPE1; Defence Science 
and Technology Laboratory) antigens produced from E. 
coli [1] and formulated into 20% (v/v) alhydrogel adjuvant. 
Both vaccines were prepared and supplied to PHE by 
Defence Science and Technology Laboratory. Two primates 
(one male, one female) were immunized with either vac-
cine on two occasions 3  weeks apart. The dose on each 
vaccination occasion was 50  μg injected intramuscularly 
in a 250  μl volume. Once an immune response was con-
firmed to have been induced via ELISA, subjects were 
anaesthetized by intramuscular injection of ketamine 
(15  mg/kg) and blood samples were collected from the 
heart prior to euthanasia by intracardiac injection of a 
lethal dose of anaesthetic (Dolelethal, 140mg/kg; Vétoquinol 
UK Ltd, Towcester, UK) in order to generate the refer-
ence stock anti-sera 56  days after primary immunization. 
The sera were collected after centrifugation of serum sepa-
ration tubes which had permitted the blood to clot. Serum 
aliquots were created and frozen at below –20°C until 
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required. Stool samples were also collected for reference 
purposes into OMNIgene GUT OMR-200 tubes.
OMV vaccines and vaccination
The immune status for each NHP was assessed with regard 
to Y. pestis antigens at 14 and 0 days before immuniza-
tion. For OMV-V/F1 vaccine studies, animals were ran-
domly allocated to groups of four (two males and two 
females per group) and were immunized with OMV-V 
or OMV-F1 vaccine formulations containing 12·5, 25 or 
50  μg of V or F1 protein via the intranasal route or with 
50  μg of V/F1 protein via the oral route in a total volume 
of 1 ml PBS. Nasal dosing of vaccine was conducted using 
a stepwise droplet method to alternate nares using a sterile 
flexible plastic tube (13GA plastic feeding tube; Instech 
Laboratories Inc., Plymouth Meeting, PA, USA) and oral 
administration was performed using a flexible dosing tube 
to ensure accurate delivery. Twenty-eight days later, all 
NHPs received a booster immunization via the same route 
of administration. Blood, stool, saliva and rectal and nasal 
swab samples were collected at days –14, 0, 28, 42 and 
at the study end-point of 56  days with body weight, tem-
perature, axillary and inguinal lymph node scores and 
haemoglobin concentration determined at each sampling 
time-point. Animals were sedated by intramuscular (i.m.) 
injection with ketamine hydrochloride (Ketaset, 100  mg/
ml; Fort Dodge Animal Health Ltd, Southampton, UK; 
10 mg/kg) for simple procedures such as blood sampling 
and vaccination that required removal from their housing. 
At the end of the study, animals were sedated with keta-
mine (15 mg/kg, i.m. administration), weighed and clinical 
data collected. Prior to euthanasia, anaesthesia was deepened 
using medetomidine hydrochloride (Sedator, 1 mg/ml; 
Dechra Veterinary Products, Shrewsbury, UK) 50  mg/kg 
and a BAL was performed. BAL fluid samples were col-
lected using a bronchoscope (Allscope XE30 4-mm flexible 
bronchoscope; VES, Rochford, UK). BAL consisted of three 
consecutive washes performed, each using 20-ml volumes 
of Hanks’ balanced salts (Sigma-Aldrich, Poole, UK), which 
was instilled in the lungs and collected. Exsanguination 
of each animal was affected via the heart before termina-
tion by the injection of a lethal dose of anaesthetic (140 mg/
kg) (Dolethal; Vétoquinol UK Ltd). At necropsy, lung, 
spleen, liver, heart, lymph nodes, kidney, brain, stomach 
and intestine were collected for histopathology and rou-
tinely processed. The tissues were stained with haematoxylin 
and eosin (H&E) and examined by light microscopy and 
evaluated subjectively by a pathologist, blinded to the 
treatments and groups in order to prevent any bias.
Statistical analysis
CE-ELISA data were analysed using Graph Pad Prism 
software version 6 and expressed as mean  ±  standard 
error of the mean (s.e.m.). Statistical comparisons were 
made using one-way analysis of variance (anova) or 
unpaired t-test. The survival data were expressed as Kaplan–
Meier survival curves and statistical significance was 
determined by log-rank test. P  <  0·05 was considered 
statistically significant. Cytokine multiplex data were ana-
lysed using one-way anova with Bonferroni’s multiple 
comparison post-test to compare PBS and rV values for 
each cytokine.
Results
Study rationale
The aim of this immunogenicity and reactogenicity study 
was to determine the suitability of OMVs produced by 
the human commensal gut bacteria, Bt, as a delivery plat-
form for plague vaccine antigens that could activate mucosal 
and systemic immune responses in an NHP host, and be 
capable of protecting against plague infection. Mice are 
a common experimental model system used in preclinical 
studies of human drugs and vaccines. However, the NHP 
model is better suited to answering key questions about 
Bt OMV vaccine efficacy and safety in humans. This is 
because the genetic relatedness of primates, and hence 
greater physiological and microbiological similarity to 
humans, requires less interpolation compared to other 
animal model systems [28–31]. Therefore, the use of NHPs 
de-risks the development pathway for Bt-OMV vaccine 
by providing assurance that the NHP microbiome and 
histological integrity of the GI tract, and other associated 
tissues, are not adversely affected following immunization. 
In addition, the use of NHP anti-sera as a surrogate to 
quantify bactericidal activity and protection against infec-
tion will help to pave the way for assessment of the 
protective effect of Bt OMV vaccination in humans.
Expression of Y. pestis vaccine antigens in Bt OMVs
It is possible to engineer Bt to target protein antigens to 
a specific location in OMVs. The antigen can be either 
secreted as a soluble protein in the lumen of OMVs by 
making a fusion with an appropriate secretory signal pep-
tide or, alternatively, it can be targeted to the surface of 
OMVs by making fusions of the antigen with OMV surface 
proteins. Accordingly, genes encoding the V and F1 Y. 
pestis proteins were successfully cloned downstream of 
sequences encoding the N-terminal signal peptides of the 
major OMV protein OmpA (BT_3852), the products of 
which were contained within the lumen or outer mem-
brane of OMVs (Fig. 1a). The constructs were generated 
in E. coli hosts and then mobilized into Bt via a triple-
filter mating protocol using a helper strain. Immunoblotting 
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of whole cell and OMV lysates of recombinant Bt strains 
confirmed expression of the V antigen (approximately 
15  μg/ml of total protein) (Fig. 1b). A dot-blot assay was 
used to detect F1 protein in OMV lysates (approximately 
10  μg/ml of total protein) with its presence being con-
firmed by LC-MS proteomics of OMV lysates (data not 
shown). The luminal versus outer membrane distribution 
of the proteins in Bt OMVs was established using a pro-
tease protection assay. This assay demonstrated that V 
protein distribution was within the lumen of OMVs (Fig. 
1c). The presence of F1 protein in extracts of F1-OMV 
was confirmed by LC-MS proteomics, with its absence in 
F1-OMV samples pretreated with proteinase K being con-
sistent with its localization to the OMV outer membrane. 
V and F1 containing OMVs had an average size of ~400 
nm (Fig. 1d) and exhibited high thermostability with 
minimal loss of vaccine antigen content after storage for 
6 weeks at either 4°C or 40°C (Fig. 1e and data not shown).
OMV immunization
OMV vaccination followed a prime and a single boost 
dosing regimen as depicted in Supporting information, 
Fig. S1, with each animal serving as their own control 
and reference for evaluating OMV vaccine responses. Levels 
of antigen-specific antibodies were assessed in serum sam-
ples obtained at two pre-immunization time-points (days 
–14 and 0) and at three time-points post-immunization 
(days 28, 42 and 56). Oral and nasal administration are 
Fig. 1. Bacteroides thetaiotaomicron (Bt) outer membrane vesicle (OMV) plague vaccines. (a) Schematic of cloning procedure for the expression 
of Yersinia virulence proteins Fraction 1 (F1) and V antigen (V) at the surface or in the lumen, respectively, of Bt OMVs. The Bt secretion signal 
sequence is indicated in yellow and is fused at the N-terminus of the F1 and V genes. (b) Expression of V antigen in OMV lysates determined by 
immunoblotting (IB). (c) Determination of protein location after treatment with proteinase K (PK). IB of V antigen with and without pretreatment of 
V-OMVs or recombinant V (rV) with proteinase K. NT = not treated. (d) Size distribution of Bt V-OMVs by nanoparticle tracking analysis. The 
OMV suspension was diluted 100 times. (e) Thermostability of V-OMVs assessed by storing preparations at different temperatures for 8 weeks prior 
to analysing OMV extracts (E) or storage buffer (B) for presence of V antigen by IB. Molecular weight (MW) is expressed in kDa. 
A. L. Carvalho et al.
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the preferred routes of vaccination to generate protective 
immunity at primary sites of plague infection [9]. To 
identify which of these routes was optimal for Bt OMV 
plague vaccines we measured both local and systemic 
antigen-specific V and F1 IgA and IgG antibodies follow-
ing delivery. For oral delivery we used a dose of 50  μg 
of V antigen formulated in Bt OMVs, which is mid-range 
of the vaccine dose used previously in cynomolgus macaques 
[32], and is equivalent to that required for a human dose 
[7]. In considering the potential risks of administering 
agents via the intranasal route and its accessibility to the 
systemic circulation and the brain, we used a range of 
OMV vaccine antigen doses (12·5, 25 and 50 μg) to assess 
safety and tolerability and determined the lowest dose 
required to induce a strong immune response.
Host response to F1-OMV plague vaccines
F1-OMV vaccine formulations were evaluated by measuring 
antigen-specific IgA levels in mucosal secretions and tissues 
and antigen-specific IgG levels in the serum (Fig. 2 and 
Supporting information, Fig. S2). F1-OMVs generated 
antigen-specific IgG serum antibodies (~0·5–1·5 μg/ml) after 
both oral and intranasal immunization at day 42 and then 
decreased (~0·5 μg/ml) at day 56. The fact that the antibody 
levels did not increase until day  42 reflects the importance 
of and requirement for a booster immunization (at day 28). 
There was no clear evidence for an effect of antigen dose 
on the levels of F1 antibodies produced, as similar levels 
of F1-specific IgG were recorded in animals receiving 12·5, 
25 or 50  μg of F1-OMVs (Fig. 2a). There was also no 
clear evidence for the superiority of oral versus nasal delivery 
of F1-OMVs in terms of levels of antigen-specific IgG 
antibodies generated (Fig. 2a). By comparison with serum 
IgG antigen-specific responses, F1-OMVs elicited weak 
mucosal immune responses with low levels of antigen-
specific IgA present in saliva (Supporting information, 
Fig. 2a–d) and BAL (Supporting information, Fig. S2e) 
samples, irrespective of the route of administration. It was 
not possible to detect F1-specific IgA antibodies in the 
salivary glands of F1-OMV immunized animals (Supporting 
information, Fig. S2f).
Host response to V-OMV plague vaccines
V-OMV vaccines generated strong antibody responses 
systemically and at mucosal sites (Fig. 3 and 4). Analysis 
of serum anti-V-specific IgG antibodies showed that the 
Fig. 2. Humoral systemic immune response to Fraction 1-outer membrane vesicles (F1-OMV) vaccines. The quantity and titre of F-antigen-specific 
immunoglobulin (Ig)G in the sera of animals immunized with F-OMVs via the intranasal or oral route was determined prior to immunization (day 
–14 ) and at three time-points post-immunization (days 28, 42 and 56) by enzyme-linked immunosorbent assay (ELISA) using an initial serum 
dilution of 1 : 10 prior to serial one in four dilutions. Data expressed as mean ± standard error of the mean (s.e.m.). *< 0·05: **< 0·01; ***< 0·001.
Gut bacteria microvesicle-based mucosal plague vaccines
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intranasal immunization route for V-OMV immunization 
generated higher titres of antibodies than oral immu-
nization (Fig. 3); in contrast, for F1-OMVs there were 
no differences in IgG responses between the two vaccine 
delivery routes (Fig. 2). The highest titres of V-specific 
IgG at the study end-point were in animals intranasally 
vaccinated with 25  μg of V-OMV, with antibody levels 
increasing over the study period (Fig. 3). In mucosal 
samples, low titres of V-specific IgA were recorded in 
the saliva at all time points analysed (Fig. 4a), with the 
highest titres being seen at day 42 (Fig. 4b). Consistent 
with the superior performance of intranasally delivered 
V-OMVs for generating V-specific IgG antibodies, higher 
levels of V-specific IgA were recorded in the saliva of 
animals immunized intranasally compared to those 
immunized via the oral route (Fig. 4a,b). The 25-μg 
dose of intranasally administered V-OMVs achieved the 
highest titres of V-specific IgA in saliva (Fig. 4a), and 
were similar to serum V-specific IgG antibody responses 
(Fig. 3). By comparison, salivary gland V-specific IgA 
antibody titres at day 56 were similar in animals immu-
nized with 12·5, 25 or 50  μg of antigen (Fig. 4c). The 
titre of V-specific IgA antibodies in the BAL were lower 
than in either the saliva or the salivary glands, with no 
evidence of vaccine dose-level-dependent responses, as 
each dose of V-OMVs elicited similarly low levels of 
V-specific IgA (Fig. 4c).
As an indicator of cell-mediated immune responses 
to OMV vaccines, we analysed the recall response of 
peripheral blood lymphocytes from animals immunized 
intranasally or orally with V-OMVs after restimulation 
with rV antigen in vitro. PBMCs from V-OMV immu-
nized animals constitutively produced varying levels of 
monocyte chemoattractant protein (MCP)-1, IL-6, IL-8 
and/or IL-23 during culture in complete media alone 
(Fig. 5). In the presence of rV, significant increases in 
the levels of IL-6 (P  <  0·0001) were seen in all PBMC 
samples irrespective of the immunization route or the 
dose of V-OMVs used. Significant increases in IL-1β 
(P  <  0·001), MCP-1 (P  <  0·0001), IL-8 (P  <  0·001) and 
IL-23 P < 0·0001) were also seen in rV-stimulated PBMC 
samples from animals immunized intranasally with the 
lowest dose of V-OMV (12·5  μg). At higher doses of 
intranasal or oral administered V-OMVs IL-8 was the 
only cytokine, in addition to IL-6, that was secreted at 
levels significantly higher (P  <  0·05) after rV stimulation 
compared to control cultures. Other cytokines included 
Fig. 3. Humoral systemic immune response to V antigen-outer membrane vesicles (V-OMV) vaccines. The quantity and titre of V-antigen specific 
immunoglobulin (Ig)G in the sera of animals immunized with V-OMVs via the intranasal or oral route was determined prior to immunization (days 
–14 and 0) and at three different time-points post-immunization (days 28, 42 and 56) by enzyme-linked immunosorbent assay (ELISA) using an 
initial serum dilution of 1 : 10 prior to serial one in four dilutions. Each line graph represents the mean value for each group (n = 4). The levels of 
V-specific IgG in individual animals immunized with 25 μg of V-OMVs via the intranasal route is shown in the bottom right graph with the 
horizontal lines in each category representing the mean ± standard error of the mean (s.e.m.).
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in the analysis that were not detected in any PBMC 
sample or were present at levels below the detection 
limit of the assay (≤  1·0  pg/ml) included IFN-γ, TNF-α, 
IL-10, IL-12p70, IL-17A and IL-18 (data not shown).
Reactogenicity of V-OMV vaccines
Biosafety of F-OMV and V-OMV vaccines were based 
on histopathology of tissue routinely recovered at necropsy 
(Supporting information, Fig. S3), and profiling of the 
resident microbial populations (microbiotas) of the GI 
and respiratory tracts using 16S rRNA sequence-based 
community profiling of faecal- and nasal swab-derived 
DNA samples taken pre- and post-OMV immunization 
(Fig. 6). Independent blinded evaluation of various tissues 
(lung, spleen, liver, heart, lymph nodes, kidney, brain and 
regions of the GI tract) at necropsy revealed no macro-
scopic signs of pathogenic infection or pathology.
Evidence of recent immune activation were seen in the 
lymphoid tissues of the spleen and lymph nodes in a 
proportion of animals in each group receiving F1-OMV 
immunization; this comprised the presence of scattered 
secondary follicles with mitotic figures and apoptotic cells 
in the splenic white pulp (Supporting information, Fig. 
S3a) and cortex of the lymph nodes (Supporting informa-
tion, Fig. S3b). Microscopic examination of tissues from 
animals receiving the highest dose of V-OMVs (50  μg) 
identified regions of organized and enlarged lymphoid 
structures and follicles within the spleen and lungs 
(Supporting information, Fig. S3f) in the absence of any 
infection or bacteria. Lymphoplasmacytic cell infiltrates 
were observed with some frequency in the mucosa of all 
parts of the GI tract (Supporting information, Fig. S3c–e); 
this is a common finding in our experience with macaques, 
and their presence probably reflects a low-grade, chronic–
active gastritis/enteritis/colitis that may or may not have 
been associated with clinical signs such as diarrhoea.
16S rRNA community profiling and bubble chart 
analysis of sequence data revealed that there was con-
siderable interindividual variation in both the nasal 
(Fig. 6a) and faecal (Fig. 6b) microbiotas of NHPs at 
baseline. Post-immunization with V-OMVs via the intra-
nasal routes did not noticeably alter the profiles of nasal 
Fig. 4. Mucosal humoral immune response to V antigen-outer membrane vesicles (V-OMV) vaccines. (a) The quantity and titre of V-antigen specific 
immunoglobulin (Ig)A in the saliva of animals immunized with V-OMVs via the intranasal or oral route was determined prior to immunization (day 
0) and at three different time-points post-immunization (days 28, 42 and 56) by enzyme-linked immunosorbent assay (ELISA) using serial one in two 
dilutions. Each line graph represents the mean value for each group (n = 4). (b) Levels of V-specific IgA in saliva samples of individual animals 
immunized with 25 μg of V-OMVs via the intranasal route. The horizontal lines in each category represent the mean ± standard error of the mean 
(s.e.m.). (c) Levels of V-specific IgA in salivary glands and bronchoalveolar lavage (BAL) samples for animals immunized intranasally or orally with 
V-OMVs analysed at day 56 post-immunization.
Gut bacteria microvesicle-based mucosal plague vaccines
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microbiota at any vaccine dose (Fig. 6a). In faecal 
microbiota the bacterial composition did not significantly 
change, although small changes in relative abundance 
were noted (Fig. 6b). For example, the average preva-
lence of Prevotellaceae increased from 30% at pre-
immunization to 44% after immunization. By contrast, 
there were decreases in the average prevalence of 
Succinivibrionaceae (from 9 to 0·4%). These findings are 
consistent with V-OMVs having a minor impact on 
resident prokaryotic communities in the upper respira-
tory tract.
Functionality of OMV-elicited IgG antibodies
Two independent assays were used to assess the func-
tionality of immune sera from OMV immunized animals 
and to determine their usefulness as potential immune 
correlates for protection in humans. The first assay used 
was a CE-ELISA [1] that quantified the ability of immune 
IgG to compete for binding to the Y. pestis V antigen. 
This assay utilizes a monoclonal antibody (mAb 7·3) which 
has previously been shown to protect mice fully by pas-
sive transfer against direct exposure to Y. pestis [33]. 
Alongside a passive transfer assay, we have previously 
demonstrated that the competitive ELISA provides a 
potential  in-vitro correlate of protection for plague [1]. 
The second assay was a prototype BCA specifically devel-
oped for this study, which assessed the level of antibody-
mediated complement killing of Y. pestis in serum samples 
using the Y. pestis reference strain CO92 as the target.
Serum samples collected at the study end-point from 
representative animals within each of the different routes 
of immunization and dose-level groups were assayed for 
their ability to displace mAb 7·3 from binding to rV in 
vitro. The data are presented as a titration line for loss 
of binding of the mouse monoclonal antibody with increas-
ing concentrations of test samples (see Materials and 
methods) using, as a reference, macaque immune sera 
obtained by parenteral immunization with rF1+ rV pro-
teins (Fig. 7). Values were also corrected for any non-
specific activity by subtracting values obtained using 
Fig. 5. Cytokine production by peripheral blood mononuclear cells (PBMCs) from V antigen-outer membrane vesicles (V-OMV)-immunized animals. 
PBMCs obtained from animals previously immunized with V-OMVs via the intranasal (i.n.) or oral route at day 56 post-immunization were cultured 
in the presence or absence [phosphate-buffered saline (PBS)] of recombinant V protein (rV) for 72 h, after which time supernatants were analysed for 
cytokine content using a multiplex bead assay and flow cytometry. Limit of detection for given values was interleukin (IL)-1β < 1·11 pg/ml, MCP-
1 < 1·61 pg/ml, IL-6 < 1·45 pg/ml, IL-8 < 1·02 pg/ml, IL-23 < 1·44 pg/ml. Given values represent the group mean ± standard error of the mean (s.e.m.) 
of duplicate samples, n = 4 per group. One-way analysis of variance (anova) with Bonferroni’s multiple comparison post-test was used to compare 
PBS and rV values for each cytokine; *P ≤ 0·05, *** P ≤ 0·001, **** P ≤ 0·0001.
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normal, non-immune, sera. The sera from animals intra-
nasally immunized with V-OMVs at all doses inhibited, 
to some extent, the binding of mAb 7·3, which at the 
higher serum concentrations were comparable to the activ-
ity of the reference sera. Sera from animals immunized 
with 25 or 50  μg of V-OMVs had the highest titres of 
Fig. 6. Bubble charts constructed using MEGAN Community Edition for 16S rRNA sequences in which the radius of each bubble is proportional to 
the number of 16S rRNA sequences obtained from animals immunized with V antigen-outer membrane vesicles (V-OMV) to visualize the degree of 
relatedness between samples. Numbers 1–16 represent individual animals. (a) Nasal microbiota of animals pre- and post-immunization with 
different vaccine doses via the intranasal route. (b) Faecal microbiota of animals pre- and post-immunization with V-OMVs via the oral route.
Gut bacteria microvesicle-based mucosal plague vaccines
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competitive antibodies (Fig. 7). In contrast, sera from 
animals immunized orally with V-OMVs had low levels, 
or no antibodies, capable of competing with mAb 7·3 
for binding to V antigen.
The BCA provided a functional activity assessment of 
the different test groups of samples taken from the immu-
nized NHPs. Throughout the assays conducted, the refer-
ence anti-sera (generated by immunizing macaques with 
recombinant rF1 and rV) provided consistent dose–
response BCA behaviour (Table 1).
There was, however, a high background BCA reactivity 
in many of the macaques at day 0 which was not specific 
to a particular housing group. Assessment of the health 
records of the study subjects did not uncover any unre-
ported health conditions and no veterinary adverse health 
observations were made. Although screened and found 
to be clear of all known high-consequence pathogens in 
primates, a routine rectal swab was able to identify 
P. aeurugenosa in one study participant. Although this 
organism was not causing disease or inducing any observ-
able clinical sign of illness, it is possible that natural 
background immunity to such a commensal could cross-
react with the type three secretion system (TTSS) com-
ponents of Y. pestis. Conservation of the TTSS has been 
discussed and demonstrated in other studies [34–37]. Thus, 
it is postulated that the high background BCA observed 
in some study animals is due to immunity to TTSS 
elements of commensal bacteria present in the colony. 
This hypothesis was further supported by ELISA, which 
confirmed that there was pre-existing immunity in some 
primates which cross-reacted with Y. pestis recombinant 
V antigen at day 0 (Fig. 3). This immunity was also 
confirmed in the CE-ELISA (Fig. 7).
Intranasal administration appeared to result in higher 
serum bactericidal responses for both OMV-antigens. All 
groups immunized with V-OMVs showed bactericidal 
activity during the study, with the best response seen at 
day 42 post-immunization in the group immunized with 
50  μg OMV-V intranasally. For F1-OMVs the data also 
suggested that an intranasal immunization dose of 25  μg 
was optimal. While day 56 BCA data (Table 1) suggested 
that there was some waning of immune functional activity 
in some groups, at day 42 almost all groups (except the 
lowest intranasally dosed F1-OMV group) appeared to 
demonstrate functional immunity to Y. pestis.
Discussion
Using bacterial OMVs generated by the bioengineering 
of the major human commensal bacterium, Bt, we have 
successfully developed formulations of plague vaccine 
antigens suitable for direct delivery to mucosal sites includ-
ing the respiratory tract, the site of pneumonic plague 
infection. Bt OMVs incorporating the V antigen generated 
robust humoral and cell-mediated immune responses in 
both the upper and lower respiratory tracts, and/or in 
the systemic circulation. Using two independent surrogate 
assays to measure levels of protection, V-OMV elicited 
properties in the sera that were important in immune 
protection, including the ability to kill Y. pestis.
Protection against pneumonic plague is essential to 
prevent epidemic spread. An outbreak in Madagascar in 
2017 resulted in more than 2400 confirmed cases of plague 
(confirmed, probable and suspected) and more than 200 
deaths; the majority (~77%) of reported cases were clini-
cally classified as pneumonic plague [38]. Foremost among 
the virulence factors secreted by Y. pestis are the F1 and 
V proteins that are pivotal in preventing phagocytosis 
(F1) and regulating type III secretion (V) by Y. pestis. 
When secreted by Y. pestis, V and other Yersinia outer 
proteins (Yops), also play roles in inhibiting cytokine 
production, platelet aggregation and apoptosis of mac-
rophages in addition to immune suppression [39]. When 
combined as purified recombinant proteins, V and F1 
represent a powerful candidate vaccine that is amenable 
to alternative formulations other than typical liquid sus-
pension with alum [40] or alhydrogel [3]; this allows for 
mucosal or dual route [41] delivery.
Using a prime and single boost oral or nasal immu-
nization protocol, V-OMVs effectively induced antigen-
specific IgA in mucosal sites and IgG in the blood; intranasal 
delivery was the most effective route of administration, 
particularly for the induction of mucosal IgA responses. 
Intranasally delivered V-OMVs were also able to elicit 
cell-mediated immune responses, as evidenced by strong 
recall responses of PBMCs from immunized animals and 
Fig. 7. A competitive enzyme-linked immunosorbent assay (ELISA) 
assay to assess the functionality of immune sera from V antigen-outer 
membrane vesicles (V-OMV)-immunized animals. Serial dilutions of 
sera from animals immunized with V-OMVs identified by individual 
code numbers shown in the key were tested for their ability to displace 
a monoclonal V antibody from the surface of the V antigen 
immobilized in microtitre plate wells. The level of competing activity 
of immune non-human primate (NHP) serum was determined after 
subtraction of the activity of non-immune serum. Reference immune 
serum was from NHPs immunized intramuscularly with recombinant 
Fraction 1 (F1) and V antigen plus adjuvant.
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the production of proinflammatory cytokines. The weaker 
immunogenicity of V-OMVs delivered via the oral route 
may reflect the more hostile environment of the GI tract 
compared with the nasal mucosa, and the need to over-
come significant physical (mechanical digestion), chemical 
(acidic/alkaline pH), biological (enzymes) and microbio-
logical (the microbiota) barriers prior to accessing inductive 
immune sites in the lower GI tract. However, despite 
these obstacles, orally delivered V-OMVs were still effec-
tive in generating functional antibodies, albeit at lower 
titres than that in animals immunized nasally with 
V-OMVs. At the earliest time-point of serological analysis 
(28 days post-immunization), systemic and mucosal anti-
body responses were established and increased over time. 
In comparison with recombinant protein-based vaccines 
[41], OMV vaccine formulations may, therefore, be less 
effective at inducing rapid-onset immune responses (i.e. 
within 14  days). However, it is possible that more inten-
sive boosting using multiple doses could be used to accel-
erate the onset of immunity and increase the strength 
and duration of immune responses (i.e. within 14  days); 
this is feasible for OMV vaccines that are non-invasive 
and more user-friendly than injected recombinant protein 
vaccines for which repeated injections would be a problem. 
Formulations of N. meningitidis-based OMV vaccine for-
mulations (MenBvac, VA-Mengoc-BC, PorA P1.6-24 and 
MeNZB) rely on a three- or four-dose immunization 
regimen to provide effective protection in children and 
adults and control of outbreaks of MenB disease [42]. 
The option to increase the concentration of V antigen 
in OMV vaccine formulations is not supported by our 
data; in terms of generating high tires of both mucosal 
and systemic antibodies intermediate dose of antigen 
(25  μg) delivered intranasally performed as well as, if not 
better than, a twofold higher dose.
The assessment of host immune responses in NHPs 
was complicated by a level of pre-existing immunity in 
some individuals prior to OMV immunization. This ‘back-
ground’ immunity was confirmed in three independent 
serum antibody assays conducted at three different labo-
ratories and sites. The health records of the study subjects 
in question did not show any health conditions and no 
veterinary health observations were made. More extensive 
investigations identified that Pseudomonas aeruginosa was 
present in some sample swabs (S.F., unpublished observa-
tions). This, however, was not accompanied by symptomatic 
infection and no veterinary interventions were required. 
Antibodies to the TTSS and the V antigen of Y. pestis 
are known to cross-react with that of other pathogenic 
Gram-negative bacteria, including P. aeruginosa, Vibrio 
species and Aeromonas species that encode homologues 
of the Yersinia V antigen [34]. While the presence of 
these bacterial species could not be confirmed in samples 
collected during the study, it is possible that they had 
infected these animals at some time prior to this study 
and were subsequently eliminated by the immune response 
they invoked; it is also possible that V-OMV vaccines 
may have been assisted by such pre-existing cross-reactive 
immunity. It is noteworthy that this phenomenon of 
‘background’ immunity was not seen in every animal.
An important immune correlate for protection by a 
candidate vaccine is the ability to generate neutralizing 
antibodies that inhibit the killing of host target cells by 
bacteria and/or are cytotoxic and can actively kill the 
bacteria [3]. We used two assays to demonstrate the gen-
eration of neutralizing antibodies in OMV-immunized 
animals. The first was a competitive ELISA in which 
immune sera from V-OMV immunized animals was able 
to compete for binding to the protective epitope in the 
V antigen with a monoclonal antibody (mAb 7·3), which 
Table 1. Summary of serum antibody bactericidal assay outputs (ED50 in units of % serum†)
Vaccine Dose (μg) Route Day 0 Day 28 Day 42 Day 56
OMV-F1 50 i.n. 12·1 36·2 14·9 >45
OMV-V 50 i.n. 0·6 5·5 0·8 14·9
OMV-F1 25 i.n. 1·4 1·6 1·5 6·2
OMV-V 25 i.n. 1·9 0·5 15·3 13·7
OMV-F1 12.5 i.n. >45 21·6 >45 39·2
OMV-V 12.5 i.n. >45 >45 20·9 22·5
OMV-F1 50 OG >45 17·0 13·0 > 45
OMV-V 50 OG >45 1·8 6·3 >45
rF1+rV Alhydrogel 50 i.n. – – – 10·7*
OG = orogastric administration; i.n. = intranasal administration; i.m. = intramuscular administration; OMV = outer membrane vesicles; OMV-V = Bt 
OMVs containing Y. pestis V antigen; OMV-F1  =  Bt OMVs containing Y. pestis Fraction 1 (F1) antigen; r  =  recombinant protein produced in 
Escherichia coli; ED50 = 50% effective dose.
*Average of six determinations; – = not included in the study design.
†the initial dilution of antibody in the assay was 45%, hence the limit of the assay was nominally set at 45%. Sera found to have an ED50 below the limit 
of detection were assigned an ED50 of > 45%.
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has previously been shown to protect mice fully by pas-
sive transfer against direct exposure to Y. pestis [1]. The 
second assay is a novel Y. pestis BCA developed specifi-
cally for this study, in which immune sera from F1- and 
V-OMV immunized NHPs were shown to kill bacteria 
via antibody-dependent complement-mediated killing 
(ADCC). Intranasally administered V-OMVs were par-
ticularly effective at generating high titres of bactericidal 
antibodies. Interpretation of the BCA data is complicated 
by the suggestion of pre-existing cross-reactive immunity 
in some of the macaques which existed before immuniza-
tion. This is evident in Fig. 3, where the group which 
eventually received intranasal vaccination with 50  μg of 
OMV-V vaccine had detectable anti-V immunity 14  days 
before vaccination and at day 0. This does not, however, 
account for all the prevaccination BCA activity. Future 
studies involving the use of mutants might be helpful in 
differentiating any cross-reactive immunity. The bacteri-
cidal activity of sera from F1-OMV immunized animals 
was perhaps surprising, in view of their weaker immu-
nogenicity and the low levels of antigen-specific antibodies 
they generated compared with V-OMV vaccines (Fig. 2). 
The low levels of F1 expression in Bt, which required 
sensitive LC-MS techniques to detect, may be a conse-
quence of inherent differences in the translational machin-
ery and requirements for efficient synthesis and/or in 
secretion sequences that were used to target newly syn-
thesized proteins to the periplasm and OMVs in Yersinia 
versus Bacteroides species. In addition, the inability of Bt 
to efficiently synthesize proteins encoded within the caf1 
operon, such as caf1M (which encodes the CafM1 protein 
that acts as a chaperone for F1 with a role in its post-
translational folding and secretion [43,44]), could also 
compromise Bt expression of F1. The inability to detect 
F1 in F1-OMV lysates using various antibodies in immu-
noblotting protocols may also be indicative of low levels 
of expression. Alternatively, it could be that the protein 
was not being expressed in its native form, or that expres-
sion of altered structural determinants resulted in the 
loss of immune epitopes following expression in Bt and 
OMVs. In summary, the results from the two independ-
ent assays provide compelling evidence for the develop-
ment of a protective immune response in OMV-immunized 
NHPs.
Studies performed with various animal species (includ-
ing NHPs [45]) indicate that, although neutralizing anti-
bodies provide protection against exposure, the 
development of cell-mediated immunity is essential for 
protection and clearance of bacteria from the host. Studies 
using mice with targeted mutations that disrupt T helper 
type 1 (Th1) or Th2 CD4 T cells responses have shown 
that Th1-driven cell-mediated immune responses are par-
ticularly important in protecting against plague [46]. The 
ability of the V protein to up-regulate IL-10 production, 
which down-regulates the generation of proinflammatory 
cytokines such as TNF-α and IFN-γ, is a key mechanism 
for virulence and immunosuppression; this contributes to 
the disruption of a balanced Th1/Th2 response which, 
alongside specific antibodies, appears to be optimal for 
protection [3]. In this context the recall response of lym-
phocytes from V-OMV immunized animals, which is 
characterized by the secretion of various proinflammatory 
cytokines, is significant and of predicted benefit to the 
mobilizing (MCP-1, IL-8) and activating (IL-1β, IL-6, 
IL-23) components of cell-mediated immune responses 
in response to plague infection in immunized animals. 
Of note, the lowest dose (12·5  μg) of intranasally admin-
istered V-OMVs was particularly effective at eliciting 
cytokine secretion by PBMCs (Fig. 5). The reasons for 
this phenomenon are unclear, but it is possible that higher 
doses of V-OMVs may have elicited qualitatively different 
(tolerogenic) immune responses similar to that described 
for other nanoparticle-based vaccine delivery systems [47].
In summary, the key findings from our study were 
that Bt OMVs could express plague antigens, and in par-
ticular the V antigen, in a stable and correct immunogenic 
form. These engineered OMV vaccine formulations elicited 
specific immune and antibody responses both in the serum 
and at mucosal surfaces, including the generation of anti-
bodies able to kill plague bacteria. Our results also highlight 
the key advantages our Bt OMV vaccine technology offers 
over available plague vaccines in terms of technology and 
approach. First, OMV vaccine delivery via oral or nasal 
administration allows for needle-free, multi-dose delivery 
that would enable mass vaccination programmes in chal-
lenging environments and at relatively low cost. 
Advantageously, this route of immunization also specifi-
cally targets the primary sites of mucosal infection which 
injectable whole-cell vaccines or subunit vaccines do not. 
Secondly, compared with subunit or whole cell vaccines, 
the manufacture and reformulation of OMV vaccines is 
quicker, and can be achieved using readily accessible and 
relatively inexpensive technology that has been commer-
cially validated in the production of licensed MenB OMV 
vaccines which are in current use [48]. Thirdly, patient 
acceptance is expected to be high, and unlike injection-
based vaccines only require out-of-clinic management. 
Fourthly, OMVs have intrinsic adjuvanticity and the ability 
to activate both the innate and adaptive arms of the 
immune system [22,23] compared with the requirement 
for chemical adjuvants such as alum to improve immu-
nogenicity of subunit vaccines. Fifthly, OMV vaccines are 
acellular and non-infectious, making them safer than live 
attenuated or killed whole cell vaccines. Finally, OMVs 
are stable for ultra-long periods in liquid and lyophilized 
form [49], and for several weeks in solution form across 
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a wide range of temperatures including 40°C. This allows 
distribution to the point of need without cold chain or 
cold storage, which is particularly important in tropical 
and low-income settings. These properties enable Bt-OMV 
vaccines to align well with the WHO Blueprint therapeutic 
product profile [11].
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Supporting Information
Additional supporting information may be found in the 
online version of this article at the publisher’s web site:
Fig. S1. Schematic of OMV plague vaccine NHP immuni-
sations via the intranasal (IN) or oral route and analyses.
Fig. S2. Mucosal humoral immune response to F OMV 
vaccine (a-d). Bronchoalveolar lavage fluid (BAL) (e) and 
salivary gland homogenates (f) were analysed for anti-
gen specific IgA at the study end point. The data shown 
represents mean ± SEM values.
Fig. S3. Histopathological sections of immunised macaques 
receiving 50 ug dose stained with H E. A. Spleen showing 
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activated splenic follicles (f) within the white pulp. B. Lymph 
node showing active lymphoid follicles(f) within the cortex. 
C. Duodenum. Lympho plasmacytic infiltration within the 
mucosa and submucosa (arrow). D. Jejunum. Lympho plas-
macytic infiltration within the mucosa and submucosa, 
showing proliferation of lymphoid follicle like structures 
(arrow). E. Ileum. Lympho plasmacytic infiltration within the 
mucosa and submucosa adjacent to activated Peyer Patches 
(arrow). F. Lung. Focal proliferation of the BALT without any 
presence of pathogen within the organ parenchyma
